Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest DCVax® Stories

2014-03-10 08:30:14

DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator BETHESDA, Md., March 10, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute ("PEI"- the FDA of Germany) of a "Hospital Exemption" early access program under Section 4b of the German Drug Law. Under this...

2013-12-16 08:26:26

Significant Differences In Technology, Trials and Company Positioning Described BETHESDA, Md., Dec. 16, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, today responded to inquiries from shareholders and investors about differences between NW Bio's technology, products and clinical trials and those of a Competitor who recently announced the results of a...

2013-11-08 08:25:30

NYU's Dr. Marc Siegel Discusses DCVax And Its Life-Extending Potential As A Cancer Therapy BETHESDA, Md., Nov. 8, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax(®) personalized immune therapies for solid tumor cancers, announced today that their vaccine was featured yesterday in news coverage on both Fox News and Fox Business News. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) The...

2013-06-13 08:28:00

MD Anderson Is The First Site; Other Sites In The US And UK To Follow BETHESDA, Md., June 13, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax(®) personalized immune therapies for solid tumor cancers, announced today that its 60-patient Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumor cancers has been initiated at The University of Texas MD Anderson Cancer Center in Houston,...

2012-09-20 02:28:52

BETHESDA, Md., Sept. 20, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it is in late stage discussions with medical centers in the U.S. and Europe to proceed with a Phase I/II clinical trial with the Company's third major product line, DCVax(®)-Direct, for all types of solid tumor cancers (i.e., cancers in any tissues). The Company previously received FDA...

2012-02-23 07:30:00

BETHESDA, Md., Feb. 23, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it now has 30 clinical trial sites open and recruiting across the United States in its ongoing Phase 2 clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company reached this milestone ahead of schedule, as the Company had projected to reach it by the end of Q1, 2012. The Company likewise met or exceeded...

2011-01-24 05:30:00

BETHESDA, Md., Jan. 24, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax® for Glioblastoma multiforme ("GBM") brain cancer. To date, this trial has been conducted at 13 clinical sites across the U.S., with 33 patients already having been enrolled. These...

2010-06-07 14:28:00

BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT") (OTC Bulletin Board: NWBO), developer of the DCVax® personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group. As part of an in-depth review of the history and competitive landscape of what he calls the "cancer vaccine revolution," Dr. Malik concludes that "NWBT has...

2009-10-21 06:00:00

BETHESDA, M.D., Oct. 21 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of...